^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PD-L1 elevation

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
1year
THERAPEUTIC EXPERIENCE WITH HEPATECTOMY FOR INTRAHEPATIC RECURRENCE AFTER RADIOTHERAPY IN LIVER TUMORS: IMPLICATION OF THERAPEUTIC EFFECT BY PD-L1 ELEVATION VIA RADIATION (AASLD 2023)
Hepatectomy for recurrence of the irradiated site after SBRT was performed successfully without complications. Although tumor immunosuppression might be induced after radiotherapy in the irradiated site for liver tumors, tumor recurrence outside the irradiated site were not observed.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD68 (CD68 Molecule)
|
PD-L1 elevation
over2years
Autophagy blockade potentiates cancer-associated immunosuppression through programmed death ligand-1 upregulation in bladder cancer. (PubMed, J Cell Physiol)
The autophagy inhibitors chloroquine (CQ) and bafilomycin A1 (Baf-A1) increased PD-L1 expression in BC cells through the ERK-JNK-c-Jun signal-transduction pathway...Our results provide evidence that autophagy blockade and its regulatory pathway affect cancer-associated immunosuppression through PD-L1 elevation. Thus, the coadministration of autophagy inhibitors and a PD-L1 immune checkpoint blockade provides a potential therapeutic approach for treating BC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MIR34A (MicroRNA 34a-5p)
|
PD-L1 expression • PD-L1 elevation • miR-34a expression • miR-34a overexpression
|
chloroquine phosphate
almost4years
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. (PubMed, Transl Oncol)
Enriched pathways were related to immune activation in responders and resistance-associated proliferation/replication in nonresponders. This preliminary work may help to generate hypotheses regarding genetically defined subsets of DLBCL, FL, and RT patients most likely to benefit from ibrutinib plus nivolumab.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • LRP1B (LDL Receptor Related Protein 1B) • EBF1 (EBF Transcription Factor 1) • KLHL14 (Kelch like family member 14)
|
TP53 mutation • PD-L1 elevation
|
Opdivo (nivolumab) • Imbruvica (ibrutinib)